Answers are grounded in this paper and cite their sources.
Hepatic ischemia‐reperfusion injury (IRI) is a major cause of postoperative liver dysfunction after hepatectomy and liver transplantation; however, effective targeted therapies are unavailable. Here, we developed a biomimetic nanoplatform, Curcumin@CeO 2 @ZIF‐8@N2 neutrophil‐derived cellular vesicles (CCZ@N2‐CVs), for targeted and multimodal protection against hepatic IRI. ZIF‐8 enables acid‐responsive curcumin release and localized Zn 2 + delivery within the injury microenvironment, and CeO 2 provides sustained antioxidant activity via Ce 3 + /Ce 4 + redox cycling. Surface coating with N2 neutrophil‐derived vesicles endows the nanoplatform with inflammation‐targeting capabilities and intrinsic immunomodulatory properties. In hepatocytes subjected to hypoxia‐reoxygenation, CCZ@N2‐CVs markedly attenuate oxidative stress, inflammatory cytokine production, and apoptosis, and restore mitochondrial membrane potential, respiratory function, and ATP generation. Moreover, the platform suppresses pro‐inflammatory macrophage polarization and promotes a reparative phenotype, thereby enhancing hepatocyte proliferation and migration. In a rat hepatic IRI model, intravenously administered CCZ@N2‐CVs preferentially accumulate in the liver and significantly mitigate tissue injury, as evidenced by reduced serum alanine aminotransferase and aspartate aminotransferase levels, decreased apoptosis, and improved histopathological outcomes. Enhanced mitochondrial metabolism and suppressed inflammatory pathways are observed in a transcriptomic analysis. Furthermore, CCZ@N2‐CVs demonstrate favorable biosafety. Collectively, this biomimetic platform exhibits ion‐mediated therapeutic nanozyme activity and establishes targeted delivery to achieve multi‐mechanistic protection against hepatic IRI.
No takes yet. Share an insight, caveat, or question.
Shen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: